Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia

Sarcoidosis is a systemic disorder of unknown aetiology characterised by the formation of non-caseating epithelioid granulomas in involved organs. Although a spontaneous remission is frequent, up to 28–53% of patients may follow a persistent active course for more than 5 years [1, 2]. Outcome may be severe in a subset of these patients. Sarcoidosis treatment relies on three lines of therapies respectively corticosteroids, immunosuppressive medications and anti-tumour necrosis factor-α (anti-TNF-α) therapy according to severity.

Source: European Respiratory Journal - December 20, 2018 Category: Respiratory Medicine Authors: Rotenberg, C., Besnard, V., Brillet, P.-Y., Giraudier, S., Nunes, H., Valeyre, D. Tags: Original Articles: Research letters Source Type: research